Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.
2.
3.

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).

Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG.

Am J Cardiol. 1995 Sep 28;76(9):54C-59C.

PMID:
7572688
4.

Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men.

Porkkala-Sarataho E, Nyyssönen K, Salonen JT.

Atherosclerosis. 1996 Jul;124(1):83-94.

PMID:
8800496
5.

Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome.

Crouse JR, Byington RP, Bond MG, Espeland MA, Sprinkle JW, McGovern M, Furberg CD.

Control Clin Trials. 1992 Dec;13(6):495-506.

PMID:
1334821
6.

Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.

MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H.

Circulation. 1998 May 12;97(18):1784-90. Erratum in: Circulation 1996 Jun 23;97(24):2479.

7.

Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.

de Groot E, Jukema JW, van Boven AJ, Reiber JH, Zwinderman AH, Lie KI, Ackerstaff RA, Bruschke AV.

Am J Cardiol. 1995 Sep 28;76(9):40C-46C.

PMID:
7572685
8.

The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.

Thallinger C, Urbauer E, Lackner E, Graselli U, Kostner K, Wolzt M, Joukhadar C.

Int J Clin Pharmacol Ther. 2005 Dec;43(12):551-7.

PMID:
16372516
9.

Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study.

Baldassarre D, Veglia F, Gobbi C, Gallus G, Ventura A, Crepaldi G, Fisicaro M, Rimondi S, Ricci G, Mancini M, Bong MG, Collatina S, Sirtori CR.

Atherosclerosis. 2000 Aug;151(2):575-83.

PMID:
10924737
10.

Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.

Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD.

Am J Cardiol. 1995 Sep 28;76(9):47C-53C.

PMID:
7572686
11.

Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.

Lankin VZ, Tikhaze AK, Kukharchuk VV, Konovalova GG, Pisarenko OI, Kaminnyi AI, Shumaev KB, Belenkov YN.

Mol Cell Biochem. 2003 Jul;249(1-2):129-40.

PMID:
12956408
12.

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD.

Am J Cardiol. 1995 Mar 1;75(7):455-9. Erratum in: Am J Cardiol 1995 Apr 15;75(12):862.

PMID:
7863988
13.

B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).

de Groot E, Jukema JW, Montauban van Swijndregt AD, Zwinderman AH, Ackerstaff RG, van der Steen AF, Bom N, Lie KI, Bruschke AV.

J Am Coll Cardiol. 1998 Jun;31(7):1561-7.

14.

Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation.

Portal VL, Moriguchi EH, Vieira J, Schio S, Mastalir ET, Buffé F, Bortolini EB, Brüch RS, Rodrigues R.

Arq Bras Cardiol. 2003 Feb;80(2):156-61, 150-5. Epub 2003 Feb 25. English, Portuguese.

15.
16.

Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).

Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J.

J Am Coll Cardiol. 2002 Feb 20;39(4):610-6.

17.

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

JAMA. 2002 Dec 18;288(23):2998-3007.

PMID:
12479764
18.

A randomized, single-blind, placebo-controlled trial of the effects of 200 mg alpha-tocopherol on the oxidation resistance of atherogenic lipoproteins.

Porkkala-Sarataho EK, Nyyssönen MK, Kaikkonen JE, Poulsen HE, Hayn EM, Salonen RM, Salonen JT.

Am J Clin Nutr. 1998 Nov;68(5):1034-41.

PMID:
9808219
19.

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators.

JAMA. 2001 Jul 4;286(1):64-70.

PMID:
11434828
20.

Lipoprotein oxidation and progression of carotid atherosclerosis.

Salonen JT, Nyyssönen K, Salonen R, Porkkala-Sarataho E, Tuomainen TP, Diczfalusy U, Björkhem I.

Circulation. 1997 Feb 18;95(4):840-5.

Supplemental Content

Support Center